Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacovigilance01:19

Pharmacovigilance

Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
Drug Regulation01:25

Drug Regulation

Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
Clinical Trials: Overview01:11

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
Clinically Relevant Drug Product Specifications: Methods of Establishment01:29

Clinically Relevant Drug Product Specifications: Methods of Establishment

Product specifications define the acceptable quality of a pharmaceutical product by ensuring identity, purity, potency, and strength. These specifications serve as benchmarks during development, manufacturing, and post-approval quality control. Clinically relevant specifications are particularly important because they directly relate to a drug's safety and efficacy in clinical use.Dissolution studies are critical biopharmaceutic tools that link in vitro behavior to in vivo performance. They...
FDA Approved Drugs: Changes to Approved Drugs01:26

FDA Approved Drugs: Changes to Approved Drugs

Post-approval, manufacturers may modify an approved new or generic drug product. Such modifications can encompass alterations in the Active Pharmaceutical Ingredient (API), manufacturing process, formulation, batch size, manufacturing site, and container closure system (FDA Guidance for Industry, April 2004). Often, a drug product may undergo multiple changes.These modifications require careful evaluation to determine their potential impact on the drug product's identity, strength, quality,...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Molecular chemisorption of N<sub>2</sub> on IrO<sub>2</sub>(110).

The Journal of chemical physics·2020
Same author

Commentary on R&D Trends Away from General Medicine/Cardiovascular Drugs: Can the FDA Help Reverse the Trend?

Clinical pharmacology and therapeutics·2017
Same author

Should recent experiences with CVOTs for oral hypoglycemic drugs allow us to rethink the regulatory paradigm?

Clinical pharmacology and therapeutics·2015
Same author

The role of academic medical centers in advancing regulatory science.

Clinical pharmacology and therapeutics·2014
Same author

Plasmid-like DNAs in the commercially important mushroom genus Agaricus.

Current genetics·2013
Same author

Material selection for acoustic radiators that are light and stiff.

The Journal of the Acoustical Society of America·2011

Related Experiment Video

Updated: Jul 14, 2026

Working with Human Tissues for Translational Cancer Research
07:48

Working with Human Tissues for Translational Cancer Research

Published on: November 26, 2015

Regulatory considerations for determining postmarketing study commitments.

R J Meyer1

  • 1FDA, Office of Drug Evaluation II, Center for Drug Evaluation and Research, Silver Spring, Maryland, USA. robert.meyer@fda.hhs.gov

Clinical Pharmacology and Therapeutics
|June 1, 2007
PubMed
Summary

Postmarketing Study Commitments (PMCs) are agreements for pharmaceutical companies to conduct studies after drug approval. Recent scrutiny focuses on their role in drug safety and regulatory oversight.

More Related Videos

A Validatable Droplet Digital Polymerase Chain Reaction Assay for the Detection of Adeno-Associated Viral Vectors in Bioshedding Studies of Tears
07:43

A Validatable Droplet Digital Polymerase Chain Reaction Assay for the Detection of Adeno-Associated Viral Vectors in Bioshedding Studies of Tears

Published on: July 14, 2023

Related Experiment Videos

Last Updated: Jul 14, 2026

Working with Human Tissues for Translational Cancer Research
07:48

Working with Human Tissues for Translational Cancer Research

Published on: November 26, 2015

A Validatable Droplet Digital Polymerase Chain Reaction Assay for the Detection of Adeno-Associated Viral Vectors in Bioshedding Studies of Tears
07:43

A Validatable Droplet Digital Polymerase Chain Reaction Assay for the Detection of Adeno-Associated Viral Vectors in Bioshedding Studies of Tears

Published on: July 14, 2023

Area of Science:

  • Pharmacovigilance and Drug Safety
  • Regulatory Science
  • Pharmaceutical Policy

Background:

  • Postmarketing Study Commitments (PMCs) are agreements made by pharmaceutical companies during FDA drug approval processes.
  • These studies aim to further characterize drug properties, with their role in drug regulation facing increased scrutiny, especially concerning drug safety.
  • While PMCs are documented in FDA regulations and approval letters, their completion is not always mandatory for sponsors, except under specific regulatory provisions.

Purpose of the Study:

  • To examine the role and regulatory implications of Postmarketing Study Commitments (PMCs) in pharmaceutical development and drug safety.
  • To analyze the evolution of PMC requirements and reporting mechanisms in response to regulatory concerns.
  • To provide an overview of the public availability and oversight of PMCs.

Main Methods:

  • Review of FDA regulations and policies pertaining to Postmarketing Study Commitments.
  • Analysis of historical practices regarding the request and agreement of PMCs during drug approval.
  • Examination of legislative actions, such as the FDA Modernization Act of 1997, impacting PMC reporting and oversight.

Main Results:

  • PMCs are commonly requested by the FDA at the time of drug approval to gain further insights into drug characteristics.
  • Public availability of PMCs is facilitated through FDA approval letters.
  • The FDA Modernization Act of 1997 enhanced reporting requirements for manufacturers and public disclosure by the FDA regarding PMC progress.

Conclusions:

  • Postmarketing Study Commitments are an integral, albeit evolving, component of pharmaceutical regulation and drug safety monitoring.
  • Increased transparency and reporting, driven by legislative action, aim to ensure accountability in fulfilling these post-approval study obligations.
  • Continued attention to PMC completion and review is crucial for robust drug safety evaluation.